FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease Mário Reis Álvares-da-Silva; Márcia da Silva Vargas; Soheyla Mohd Souza Rabie; Gabriella Jonko; Patricia Gabriela Riedel; Larisse Longo; Marcelo Rodrigues Gonçalves; Vivian Cristine Luft; Dvora Joveleviths;

Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents Diego García-Compeán; Ramesh Kumar; Ángel Noe del Cueto-Aguilera; Héctor Jesús Maldonado-Garza; Jesús Zacarías Villarreal-Pérez;

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;